Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-15T11:40:21.690Z Has data issue: false hasContentIssue false
  • English
  • Français

Presence of 2,5-dimethoxy-4-bromoamphetamine (DOB) among samples brought for drug checking in Spain

Published online by Cambridge University Press:  23 March 2020

P. Quintana-Mathé ,
M. Grifell-Guardia ,
Á. Palma-Conesa ,
C. Gil-Lladanosa ,
I. Fornís-Espinosa ,
F. Caudevilla-Galligo ,
L. Gallindo-Guarin ,
M. Farre-Albaladeo ,
M. Ventura-Vilamala  and
M. Torrens-Melich
P. Quintana-Mathé
Affiliation:
Institut Català de la Salut ICS, EAP Raval Sud, Barcelona, Spain Associació Benestar i Desenvolupament ABD, Energy Control EC, Barcelona, Spain
M. Grifell-Guardia*
Affiliation:
Associació Benestar i Desenvolupament ABD, Energy Control EC, Barcelona, Spain Parc de Salut Mar, Institut de Neuropsiquiatria i Addiccions INAD, Barcelona, Spain Hospital del Mar Medical Research Institute IMIM, Grup de recerca en Addiccions, Barcelona, Spain
Á. Palma-Conesa
Affiliation:
Parc de Salut Mar, Institut de Neuropsiquiatria i Addiccions INAD, Barcelona, Spain Hospital del Mar Medical Research Institute IMIM, Grup de recerca en Addiccions, Barcelona, Spain
C. Gil-Lladanosa
Affiliation:
Associació Benestar i Desenvolupament ABD, Energy Control EC, Barcelona, Spain
I. Fornís-Espinosa
Affiliation:
Associació Benestar i Desenvolupament ABD, Energy Control EC, Barcelona, Spain
F. Caudevilla-Galligo
Affiliation:
Associació Benestar i Desenvolupament ABD, Energy Control EC, Barcelona, Spain
L. Gallindo-Guarin
Affiliation:
Parc de Salut Mar, Institut de Neuropsiquiatria i Addiccions INAD, Barcelona, Spain Hospital del Mar Medical Research Institute IMIM, Grup de recerca en Addiccions, Barcelona, Spain Universitat Autònoma de Barcelona UAB, Bellaterra, Spain
M. Farre-Albaladeo
Affiliation:
Universitat Autònoma de Barcelona UAB, Bellaterra, Spain Hospital Universitari Germans Trías i Pujol, Farmacologia Clínica, Barcelona, Spain
M. Ventura-Vilamala
Affiliation:
Associació Benestar i Desenvolupament ABD, Energy Control EC, Barcelona, Spain Hospital del Mar Medical Research Institute IMIM, Grup de recerca en Addiccions, Barcelona, Spain
M. Torrens-Melich
Affiliation:
Parc de Salut Mar, Institut de Neuropsiquiatria i Addiccions INAD, Barcelona, Spain Hospital del Mar Medical Research Institute IMIM, Grup de recerca en Addiccions, Barcelona, Spain Universitat Autònoma de Barcelona UAB, Bellaterra, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

New Psychoactive Substances (NPS) appear to be increasing in popularity because they mimic the effect of traditional drugs. DOB is a world-wide controlled phenethylamine, with agonist activity in 5HT2A receptors. Its effects are comparable to those of LSD, with dosage range 1.0–3.0 mg and duration 18–30 h.

Objective

To assess the presence of DOB in the substances submitted to, and analyzed by, energy control.

Materials and methods

All samples presented to Energy Control (EC) from August 2009 to August 2015 were analyzed. EC is a spanish harm-reduction non governmental organization that offers to users the possibility of analyzing the substances they intend to consume. Samples in which DOB was detected using gas chromatography-mass spectrometry were selected for this study.

Results

From a total of 20,062 samples, 13 contained DOB (0,06%), with no clear variations among the years studied. The samples were mostly sold as DOC(8), DOB(2) and LSD(2). Nine out of total 13 samples presented as blotter.

Conclusion

Results suggest that availability of DOB in the Spanish drug market is anecdotic. Nonetheless, a number of the samples containing DOB were not sold as such, increasing the possibility of side effects, as users may ignore which substance they are actually using. When a patient presents at an Emergency Department with persistent hallucinogenic symptomatology after ingesting a blotter, psychiatrist should be aware of long-lasting psychedelics such as DOB.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW237
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S171
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.